1 We now report 10-year all-cause death results.
2 We now report 5-year outcomes in the trial.
3 We now report a competing rearrangement, revealed by CASPT2(1
4 We now report a high-yielding, prebiotic synthesis of cystein
5 We now report adoptively transferred T cells or whole splenoc
6 We now report ADPGK knock-out Ramos BL cells display abated i
7 We now report efforts to rationally design this construct tow
8 We now report final survival outcomes.
9 We now report in contrast, E-selectin directly triggers signa
10 We now report Raf kinase as the direct target of atRA-Crabp1.
11 We now report somatic SMAD3 mutations in bone lesions of four
12 We now report that (1) S-nitrosothiols covalently modify both
13 We now report that activation of mGlu(3) induces long-term de
14 We now report that aggregates of Medin also develop in the ao
15 We now report that ClpS binds, and ClpSAP degrades, proteins
16 We now report that cyclization of pivaldimino-amides with pho
17 We now report that deletion of genes encoding the E-protein t
18 We now report that EROCOC(17+4) mixed with 10% (w/w) choleste
19 We now report that genes for multiple and unique P450s occur
20 We now report that homozygous deletion of Ubiad1 is produced
21 We now report that HOPS binds each of the four SNAREs.
22 We now report that HOPS-dependent fusion occurs with Ypt7 anc
23 We now report that in a lethal mouse model H84T is indeed non
24 We now report that in a manner consistent with findings in pa
25 We now report that increased acetylcholine during liquid grow
26 We now report that increased expression of the beta 6 class V
27 We now report that inhibition of astrocytic Phgdh suppressed
28 We now report that mice deficient in conventional T lymphocyt
29 We now report that nestin selectively facilitates phosphoryla
30 We now report that osteocytic Panx1 deletion (Panx1(Deltaot))
31 We now report that PA also induces conformational changes in
32 We now report that pironetin has a short half-life (<7 min) i
33 We now report that secreted SOD1 is functionally active and a
34 We now report that the ability of M(4) to inhibit dopamine re
35 We now report that vascular smooth muscle cells express all t
36 We now report that we fail to confirm the association of rs10
37 We now report the full 15-year follow-up.
38 We now report the high-resolution (1.53-2.20 angstrom) crysta
39 We now report the identification and preclinical evaluation o
40 We now report the largest cohort of patients undergoing EVM-g
41 We now report the local effects of dupilumab on type 2 inflam
42 We now report the location of this TAM as well as the pleiotr
43 We now report the long-term outcome of the patients recruited
44 We now report the successful adaptation of this chromatin imm
45 We now report the synthesis of sulfonyl- and cyano-substitute
46 We now report the synthesis of the tetramic acid PF-1018 thro
47 We now report their longer-term outcomes including a 20 patie
48 We now report their longer-term outcomes, including a 20-pati
49 We now report three unrelated children with severe neurodegen
50 We now report updated 5-year outcomes of the trial.